Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

3D software helps cardiologists plan ahead for TAVR complications
Serious complications are rare after TAVR, but they can be catastrophic or fatal when they do occur. The care team at Sentara Heart Hospital found that bringing in new 3D software made it much easier to plan ahead for such issues.
FDA clears AI-powered platform that personalizes care during TAVR, cardiac pacing procedures
The newly cleared CARA System from Cara Medical was designed to help clinicians before and during a variety of cardiac procedures. It provides a personalized 3D map of the patient's cardiac conduction system and then overlays that map onto live fluoroscopic images.
PFO closure after thromboembolism linked to strong 20-year outcomes
Recurrent strokes and TIAs were rare, though bleeding events among women did stand out as a trend to watch going forward.
TAVR a safe treatment option for patients who have undergone chest radiation therapy
In fact, researchers wrote, TAVR and SAVR were linked to comparable long-term outcomes for heart patients who have previously been exposed to mediastinal radiation.
Registry data point to ‘striking shift’ in treatment decisions after FDA approved low-risk TAVR
Many experts still recommend SAVR over TAVR for patients younger than 65 years old with severe aortic stenosis. However, transcatheter treatments are growing more and more popular when these younger patients require a valve replacement.

Medtronic's Evolut Pro TAVR valve treating aortic stenosis

TAVR linked to higher reintervention rate than SAVR in Evolut Low Risk trial update

The Evolut Low Risk trial has been one of cardiology’s most closely watched studies for years now. For the first five years after treatment, TAVR and SAVR were associated with comparable outcomes when treating low-risk patients. In this new six-year update, however, TAVR was linked to a heightened risk of reintervention not seen with SAVR.

A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]

Cardiologists propose new 'coronary risk zone' approach for redo TAVR planning

Redo TAVR can be challenging, requiring a significant amount of preprocedural CT planning. This proposed framework was designed to simplify that planning and help interventional cardiologists thrive.

REVENUE MONEY INCREASE DOLLAR GRAPH FINANCE

Edwards celebrates double-digit TAVR sales growth in Q4

It was another strong quarter for Edwards Lifesciences as the company's TAVR platform continues to gain momentum. The FDA's approval of multiple Edwards valves for the treatment of asymptomatic severe AS represents a potential game-changer for the entire industry.

Stroke risk after TAVR still higher for woman as ‘sex paradox’ lives on

By tracking sex-related differences after TAVR, researchers hope to refine patient selection strategies and optimize care for both men and women.

TAVR valve for AR , a recent Edwards acquisition, delivers long-term value

The J-Valve System is associated with positive 10-year outcomes for patients with severe AR, according to new research out of China. It also performs well in patients with severe AS.

SAVR linked to ‘excellent’ long-term survival for patients with bicuspid aortic valves

Survival rates are high for both men and women presenting with BAV disease, according to a new analysis of nearly 28,000 SAVR patients.

Medtronic SVP Nina Goodheart to retire after nearly 20 years in cardiovascular care

Nina Goodheart, the president of Medtronic’s structural heart and aortic business, has announced her retirement.

Transcatheter treatment of tricuspid valve disease has rapidly evolved over the past two years, giving physicians new tools to address a condition long considered under treated due to limited procedural options and complex anatomy. Ryan K. Kaple, MD, FACC, FSCAI, director of the structural and congenital heart program at Hackensack University Medical Center, spoke top Cardiovascular Business about recent advances and his center's real-world experience.

Key trends in transcatheter tricuspid valve repair and replacement

The interventional treatment of tricuspid valve disease has evolved in recent years thanks to new research and critical FDA approvals. Cardiologist Ryan Kaple, MD, reviewed this trend for a new video interview.

Structural Heart Disease

3D software helps cardiologists plan ahead for TAVR complications

FDA clears AI-powered platform that personalizes care during TAVR, cardiac pacing procedures

PFO closure after thromboembolism linked to strong 20-year outcomes

TAVR a safe treatment option for patients who have undergone chest radiation therapy

Registry data point to ‘striking shift’ in treatment decisions after FDA approved low-risk TAVR